NCT00203320已完成1 期
Etanercept for Alzheimer's-Type Memory Loss Pilot Study II
Tobinick, Edward Lewis, M.D.2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2005年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- MMSE
研究概览
简要总结
It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.
详细描述
Etanercept, a biologic anti-TNF fusion protein, will be administered weekly or biweekly by perispinal injection to a maximum of 30 study subjects for a period of one year with serial testing of cognition and function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 0 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •NINCDS-ADRDA Criteria for Alzheimer's disease
- •CT or MRI consistent with AD
排除标准
- •active infection
- •demyelinating disease
- •uncontrolled diabetes mellitus
- •vascular dementia
- •clinically significant neurologic disease other than AD
- •Hachinski >4
- •history of lymphoma
- •wbc<2500
- •platelets<100,000
- •pregnancy
- •premenopausal, fertile not on acceptable birth control
- •change in neuroactive medication within 4 weeks of study initiation
结局指标
主要结局
MMSE
ADAS-Cog
SIB
ADCS-ADLsev
次要结局
- Category fluency
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
TNF-Alpha Inhibition for Treatment of Alzheimer's DiseaseAlzheimer's DiseaseNCT00203359Tobinick, Edward Lewis, M.D.15
已完成
不适用
Attenuation of Inflammatory Processes Associated With Alzheimer's Disease After Consumption of Pomace Olive Oil.Alzheimer DiseaseNCT04559828National Research Council, Spain20
Unknown
不适用
Neuroinflammation and Alzheimer's Pathology in POCDPost-Operative ConfusionNeuroinflammatory ResponseAlzheimer DiseaseNCT05378659University of Tennessee Graduate School of Medicine120
已完成
不适用
Inflammatory Markers and Level of Cortical HyperactivityCognition DisorderNCT05991830University of Chile20
已完成
1 期
Low Dose IL2 Immunotherapy in ADAlzheimer DiseaseNCT05821153The Methodist Hospital Research Institute8